Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

samotolisib (LY3023414)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eli Lilly

Drug class:

mTOR inhibitor, PI3K inhibitor

Related drugs:

‹

everolimus (138)

temsirolimus (37)

PF-05212384 (31)

GSK2126458 (17)

PF-04691502 (6)

niclosamide (1)

rapamycin topical (0)

ridaforolimus (0)

encapsulated rapamycin (0)

inhibitors of the PI3K/AKT/mTOR pathway (0)

albumin-bound (0)

enzastaurin (3)

BAY 1082439 (1)

›

PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	LY3023414 Sensitive: C3 – Early Trials LY3023414 Sensitive : C3	LY3023414 Sensitive: C3 – Early Trials LY3023414 Sensitive : C3
PIK3R1 mutation	Endometrial Cancer	PIK3R1 mutation	Endometrial Cancer	LY3023414 Sensitive: C3 – Early Trials LY3023414 Sensitive : C3	LY3023414 Sensitive: C3 – Early Trials LY3023414 Sensitive : C3
PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	ACR-368 + LY3023414 Sensitive: C3 – Early Trials ACR-368 + LY3023414 Sensitive : C3	ACR-368 + LY3023414 Sensitive: C3 – Early Trials ACR-368 + LY3023414 Sensitive : C3
BRCA2 mutation	Ovarian Serous Adenocarcinoma	BRCA2 mutation	Ovarian Serous Adenocarcinoma	ACR-368 + LY3023414 Sensitive: D – Preclinical ACR-368 + LY3023414 Sensitive : D	ACR-368 + LY3023414 Sensitive: D – Preclinical ACR-368 + LY3023414 Sensitive : D
PIK3CA mutation	Endometrial Cancer	PIK3CA mutation	Endometrial Cancer	LY3023414 Sensitive: D – Preclinical LY3023414 Sensitive : D	LY3023414 Sensitive: D – Preclinical LY3023414 Sensitive : D